APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
505809 25 µg 36€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505810 100 µg 106€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  2. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  3. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  4. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  5. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  6. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  7. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  8. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  9. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  10. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  11. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  12. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  13. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  14. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  15. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  16. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  17. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  18. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  19. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  20. Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
  21. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  22. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  23. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  24. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  25. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  26. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  27. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  28. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  29. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  30. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  31. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  32. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  33. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  34. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  35. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  36. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  37. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  38. Diao L, et al. 2022. iScience. 25:105511. PubMed
  39. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  40. Gu M, et al. 2021. Nat Immunol. 22:193. PubMed
  41. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  42. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  43. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  44. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  45. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  46. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  47. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  48. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  49. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  50. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  51. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  52. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  53. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  54. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  55. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  56. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  57. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  58. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  59. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  60. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  61. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  62. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  63. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  64. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  65. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  66. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  67. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  68. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  69. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  70. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  71. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  72. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  73. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  74. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  75. Mills C, et al. 2022. Cells. 11:. PubMed
  76. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  77. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  78. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  79. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  80. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  81. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  82. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  83. Harty J 2009. Infect Immun. 77:1894. PubMed
  84. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  85. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  86. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  87. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  88. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  89. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  90. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  91. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  92. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  93. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  94. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  95. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  96. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  97. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  98. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  99. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  100. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  101. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  102. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  103. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  104. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  105. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  106. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  107. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  108. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  109. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  110. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  111. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  112. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  113. Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
  114. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  115. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  116. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  117. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  118. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  119. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  120. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  121. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  122. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  123. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  124. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  125. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  126. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  127. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  128. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  129. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  130. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  131. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  132. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  133. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  134. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  135. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  136. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  137. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  138. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  139. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  140. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  141. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  142. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  143. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  144. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  145. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  146. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  147. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  148. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  149. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  150. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  151. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  152. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  153. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  154. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  155. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  156. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  157. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  158. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  159. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  160. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  161. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  162. Gupta S, et al. 2022. Life Sci. 288:120182. PubMed
  163. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  164. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  165. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  166. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  167. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  168. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  169. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  170. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  171. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  172. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  173. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  174. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  175. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  176. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  177. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  178. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  179. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  180. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  181. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  182. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  183. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  184. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  185. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  186. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  187. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  188. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  189. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  190. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  191. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  192. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  193. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  194. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  195. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  196. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  197. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  198. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  199. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  200. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  201. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  202. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  203. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  204. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  205. Yang N, et al. 2021. NPJ Precis Oncol. 5:37. PubMed
  206. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  207. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  208. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  209. Sheng J, et al. 2021. eLife. 10:00. PubMed
  210. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  211. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  212. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  213. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  214. Yang L, et al. 2021. Front Immunol. 12:722273. PubMed
  215. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  216. Tang L, et al. 2022. Front Immunol. 12:770402. PubMed
  217. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  218. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  219. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  220. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  221. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  222. Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed
  223. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  224. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  225. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  226. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315404 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account